Early anxiety screening in pediatric primary care improves detection, outcomes, and access to mental health support starting at age 8. A new narrative review presented at the 2025 NAPNAP National ...

In the final part of this 5-part series, panelists discuss new allergy treatments such as Xolair, early immunotherapy, and their broader impact. Emerging research in food allergy and anaphylaxis is ...

In part 4 of this 5-part series, panelists discuss gaps in pediatric food allergy care, stressing better diagnosis, education, and management. Advances in pediatric food allergy and anaphylaxis ...

In part 2 of this 5-part series, panelists discuss confusion in food allergy diagnosis and the need for better medical education. In this Contemporary Pediatrics and HCPLive RX Review discussion, ...

In part 3 of this 5-part series, panelists discuss the recent Neffy approval, oral immunotherapy, and Xolair’s role in allergy management. Traister notes that while intranasal epinephrine offers a ...

In part 1 of this 5-part series, panelists discuss early allergen introduction, oral immunotherapy, and Xolair for food allergy. The role of needle-free epinephrine in pediatric allergy for 2025 ...

Mary Koslap-Petraco highlighted the need to address vaccine hesitancy, catch up on immunizations, and build trust with parents at the 2025 NAPNAP National Conference on Pediatric Health Care. At the ...

If approved, SYD-101 would be the first and only pharmaceutical option for the treatment of progression of pediatric myopia in the United States. Sydnexis has announced that the FDA has accepted its ...

Mary Koslap-Petraco, DNP, PPCNP-BC, CPNP, FAANP, reacts to the recent cancelations of the ACIP and VRBPAC and comments on the potential down stream effects. The ACIP meeting was originally slated for ...

At the 2025 NAPNAP National Conference, Maureen Madden, DNP, CPNP-AC, CCRN, FCCM, FAAN, provides the key takeaways and recommendations for glycemic control guidance, updated in 2024. In this video ...

In part 2 of this 5-part series, panelists discuss confusion in food allergy diagnosis and the need for better medical education. In part 3 of this 5-part series, panelists discuss the recent Neffy ...

The study, known as BRAVE-AA-PEDS, was sponsored by Eli Lilly and Company and involved 257 adolescents aged 12 to under 18 years. Baricitinib, an oral Janus kinase (JAK) inhibitor, demonstrated ...